ADAM17 and hypertrophy: Compared with control mice, vascular ADAM17-deficient mice and ADAM17 antibody treated mice show alleviated cardiac hypertrophy, vascular medial hypertrophy, and perivascular fibrosis induced by Ang II via activating EGFR, which is independent of blood pressure regulation [14, 15].